FDA issues guidance on MATs for opioid use disorder

FDA issued new draft guidance for sponsors developing medication-assisted treatments (MATs) for opioid use disorder. According to the agency, regular adherence to MATs plus social, medical and psychological services could be effective

Read the full 321 word article

User Sign In